Bristol-Myers Squibb Company (NYSE:BMY) FY Conference September 23, 2025 09:40 AM ET Company ParticipantsLynelle Hoch - President - Cell Therapy OrganizationConference Call ParticipantsCourtney Breen - Senior Research AnalystCourtney BreenThank you all so much for being here. Lynelle, thank you so much for being here with us today. For those of you who don't know me, my name is Courtney Breen. I am the Large Cap Analyst here at Bernstein covering all of our U.S. names, Bristol included. I am very, very prou ...

Qualigen Therapeutics (QLGN) shares soared about 200% on Monday at the peak after the biotech company secured a $41 million investment from Faraday Future (FFAI) and its founder YT Jia. Investors cheered QLGN also because it’s rebranding as CXC10 as part of a major pivot into crypto-Web3, revealing three growth engines: a crypto treasury, a DeAI trading platform, and ecosystem tokens. More News from Barchart QLGN stock has since reversed much of the post-announcement gains, but is still trading up nearl ...

Wilmington, Delaware-based Incyte Corporation (INCY) is a biopharmaceutical company that discovers, develops, and commercializes treatments in oncology, inflammation, and autoimmune diseases. Valued at a market cap of $16.5 billion, the company’s portfolio includes drugs such as Jakafi, Monjuvi, Pemazyre, and Opzelura. Companies valued at $10 billion or more are typically classified as “large-cap stocks,” and Incyte fits the label perfectly, with its market cap exceeding this threshold, underscoring its s ...

SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential legal claims on behalf of Capricor Therapeutics, Inc. (NASDAQ: CAPR) shareholders, concerning alleged misconduct by certain officers and directors that may have harmed the company and its investors. Investors who have continuously held Capricor shares since before October 9, 2024, may have legal rights and are encouraged to contact the firm to learn more:https://www.johnsonfistel.com/investigations/capricor-therape ...

Key Takeaways Tempus AI gained FDA clearance for its RNA sequencing-based xR IVD device. TEM's xR IVD detects gene rearrangements in tumor tissues from solid malignancies.The device bolsters Tempus AI's role in oncology research and drug development. RNA sequencing provides a comprehensive view of biological information, offering deeper insights into disease mechanisms, including improved fusion detection. As a powerful tool in research and development, RNA analysis helps identify molecular pathways and ne ...

Illumina and pharma partners will develop companion diagnostics for historically important KRAS biomarker SAN DIEGO , Sept. 23, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN)Â will partner with multiple global pharmaceutical companies to develop companion diagnostics (CDx) enabled on the TruSight™ Oncology (TSO) Comprehensive genomic profiling test. ...

Fifty 1 Labs continues to advance its portfolio of biotech and wellness initiativesVANCOUVER, British Columbia, Sept. 23, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty 1 Labs, Inc, (OTC:FITY) a Nevada-based holding company revolutionizing health, wellness, and biotech through AI-driven drug repurposing and functional medicine, today announced that it has signed a letter of engagement with a Public Company Accounting Oversight Board (PCAOB) registered auditing firm. The engagement covers audits of the Company's ...

The KINECT-PROâ"¢ analysis is the first and only of its kind to report both remission of tardive dyskinesia symptoms and associated improvements in patient-reported outcomes. Post-hoc analysis from KINECT-PRO demonstrated substantial symptomatic remission rates at Week 24, even earlier than previous studies have reported. ...

SALT LAKE CITY and BOSTON , Sept. 23, 2025 /PRNewswire/ -- Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test. ...

- Non-exclusive license for Solid’s proprietary, next generation capsid, AAV-SLB101, to accelerate development of Kinea Bio’s gene therapy for dysferlin-related limb-girdle muscular dystrophy - - Solid to receive an upfront payment and is eligible for certain development and sales milestones and tiered royalties on net sales -- Solid continues to expand collaborative efforts for AAV-SLB101 with more than 25 agreements and licenses executed to date - CHARLESTOWN, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Sol ...